Cetuximab
Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company. In the United States, a regimen of cetuximab costs approximately $30,790 for an eight-week course.
| Trivial name | IGHG1 |
| Catalog Number | TP-079CL |
| Alternative Name(s) | Cetuximab |
| Research Area | Cancer |
| Molecular Formula | C6484H10042N1732O2023S36 |
| CAS# | 205923-56-4 |
| Purity | >90% |
| Size | 1 mg |
| Supplier Page | https://www.creativebiolabs.net/Cetuximab-22417.htm |
| Additional Information | Cetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. |